组织型纤溶酶原激活剂和茴香酰化纤溶酶原链激酶激活剂复合物对急性心肌梗死死亡率的影响。

Effects of tissue-type plasminogen activator and anisoylated plasminogen streptokinase activator complex on mortality in acute myocardial infarction.

作者信息

Held P H, Teo K K, Yusuf S

机构信息

Clinical Trials Branch, National Heart, Lung and Blood Institute, Bethesda, Md 20892.

出版信息

Circulation. 1990 Nov;82(5):1668-74. doi: 10.1161/01.cir.82.5.1668.

DOI:10.1161/01.cir.82.5.1668

PMID:2146038

Abstract

An overview of eight randomized controlled trials of tissue-type plasminogen activator (Alteplase or Duteplase) and 10 of anisoylated plasminogen streptokinase activator complex (Anistreplase) showed that the odds of early death were reduced by 29% by tissue-type plasminogen activator and 46% by anisoylated plasminogen streptokinase activator complex, with overlapping 95% confidence intervals. Although the beneficial effects of both agents are consistent and are strengthened when all the trials are considered together, the available data do not permit comparisons of the relative efficacy of these two agents with each other or with streptokinase.

摘要

一项对八项组织型纤溶酶原激活剂（阿替普酶或杜替普酶）随机对照试验以及十项茴香酰化纤溶酶原链激酶激活剂复合物（茴酰栓溶酶）随机对照试验的综述表明，组织型纤溶酶原激活剂可使早期死亡几率降低29%，茴香酰化纤溶酶原链激酶激活剂复合物可使其降低46%，二者95%置信区间有重叠。尽管两种药物的有益效果是一致的，且将所有试验综合考虑时会得到强化，但现有数据无法对这两种药物彼此之间或与链激酶的相对疗效进行比较。